Catalyst Dossier · compiled by CeliA 🧫

BioCryst Pharmaceuticals, Inc. (BCRX)

Biological Products, (No Diagnostic Substances) · market cap $2.3B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-03

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

BioCryst Pharmaceuticals (BCRX) is a Durham, NC-based rare disease biotech with 110 employees and a ~$2.5B market cap. The company commercializes Rapivab (peramivir) and has built a pipeline anchored on BCX7353 (berotralstat) for hereditary angioedema (HAE), which appears to be a marketed or near-commercial asset given the dramatic 2025 revenue surge to $875M vs. $451M in 2024. The balance sheet shows $171.6M cash against net debt of $223.6M and only ~8 months of runway, making capital management a near-term overhang.

The catalyst path

2026-08-03Earningsimp 5/10

Pipeline

Asset	Phase	Indication
BCX7353	Phase 3	Hereditary Angioedema (HAE)
Allopurinol	Phase 2	Gout
Peramivir 200 mg	Phase 2	Influenza
BCX4208	Phase 2	Gout
Oseltamivir	Phase 3	Influenza
BCX7353 capsules	Phase 3	Hereditary Angioedema, HAE
Forodesine 200 mg	Phase 2	Cutaneous T-cell Lymphoma (CTCL),
ulodesine	Phase 2	Gout
Peramivir	Phase 3	Influenza
forodesine HCl	Phase 2	Chronic Lymphocytic Leukemia (CLL)
Peramivir 150 mg	Phase 2	Influenza
forodesine hydrochloride	Phase 2	Lymphoma
BCX-1777	Phase 2	Leukemia, Lymphocytic
BCX4161	Phase 3	Hereditary Angioedema
forodesine hydrochloride (BCX-1777)	Phase 2	Leukemia, T-Cell
Ulodesine (BCX4208) 5 mg	Phase 2	Gout
Berotralstat	Phase 3	Hereditary Angioedema
BCX9930	Phase 2	Paroxysmal Nocturnal Hemoglobinuria

Price & technical context

3-month

+1.4%

6-month

+25.2%

12-month

+7.0%

52-wk range

$6.24–$10.00

vs 50-day MA

+8.0%

vs 200-day MA

+20.7%

Realized vol

46.6%

Max drawdown

-44.2%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BCRX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.